Theodorakis and Nikolaou highlight that SGLT2 inhibitors, such as dapagliflozin and empagliflozin, significantly reduce hospitalizations for heart failure (HF), slow progression of renal disease, and lower the risk of major adverse cardiovascular events (MACE) [21]. This evidence concerns the gene SLC5A2 and heart failure.